TrkB is the cognate receptor for brain-derived neurotrophic factor (BDNF), a member of the neurotrophin family involved in neuronal survival, neurogenesis and synaptic plasticity. BDNF has been shown to protect photoreceptors from light-induced retinal degeneration (LIRD) and to improve ganglion cell survival following optic nerve damage. However, the utility of BDNF as a retinal neuroprotectant is limited by its short half-life, inability to cross the blood-brain and bloodretinal barriers, and activation of the proapoptotic p75 neurotrophin receptor. N-Acetylserotonin (NAS) is a naturally occurring chemical intermediate in the melatonin biosynthetic pathway in the pineal gland and retina. Its synthesis occurs in a circadian fashion with high levels at night and is suppressed by light exposure. Until recently, NAS was thought to function primarily as a melatonin precursor with little or no biological function of its own. We have now shown that TrkB activation in the retina and hippocampus is circadian in C3H/f +/+ mice, which synthesize NAS, but not in C57BL/6 mice, which have a mutation in the gene encoding the enzyme that converts serotonin to NAS. In addition, treatment of mice exogenous NAS, but not with serotonin or melatonin, activates TrkB during the daytime in a BDNF-independent manner. NAS appears to have neuroprotective properties and its administration reduces caspase 3 activation in the brain in response to kainic acid, a neurotoxic glutamate analog. We have developed structural analogs of NAS that activate TrkB. One of these derivatives, N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]-2oxopiperideine-3-carboximide (HIOC), selectively activates TrkB with greater potency than NAS and has a significantly longer biological half-life than NAS after systemic administration. HIOC administration results in long-lasting activation of TrkB and downstream signaling kinases. The compound can pass the blood-brain and blood-retinal barriers when administered systemically and reduces kainic acid-induced neuronal cell death in a TrkB-dependent manner. Systemic administration of HIOC mitigates LIRD, assessed electrophysiologically and morphometrically. Hence, NAS may function as an endogenous circadian neurotrophin-like compound and HIOC is a good lead compound for further drug development for treatment of retinal degenerative diseases.
Introduction
Melatonin is a neurohormone synthesized in the retina and pineal gland [1;2] . It transmits circadian signals of darkness and nighttime. Melatonin is synthesized from serotonin and its robust circadian rhythm is attributable primarily to the circadian regulation of arylalkylamine N-acetyltransferase (AANAT) [3] , which converts serotonin to Nacetylserotonin. Melatonin acts primarily through two subtypes of G protein-coupled receptors, MT1 and MT2 [4;5] , but the neurohormone may also have actions as a free radical scavenger and antioxidant [5] . Until recently, N-acetylserotonin was thought to be merely a metabolic intermediate in melatonin synthesis, although some data suggest that it may have cytoprotective effects due to its antioxidant properties [6] .
Neurotrophins are a family of small proteins with neuroprotective effects that play important roles in development and maintenance of neurons, in neuroprogenitor cell proliferation and neurogenesis, and in a variety of other important neuronal functions [7] . Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family that acts primarily on high-affinity tropomyosin-related kinase B (TrkB) receptors, which are transmembrane proteins with an extracellular BDNF-binding domain and an intracellular tyrosine kinase domain [7;8] . Binding of BDNF elicits homodimerization of TrkB and its autophosphorylation. Phospho-TrkB (pTrkB) couples to multiple signaling pathways, including ERK1/2 and AKT, through which it is thought to promote cell survival. BDNF also acts on the low affinity p75 NTR receptor, which is also a tyrosine kinase receptor [7] .
BDNF has been shown to protect against LIRD and to improve retinal ganglion survival following optic nerve injury through TrkB-dependent mechanisms [9] [10] [11] [12] . However, the therapeutic potential of BDNF is limited because (1) it does not cross the blood-retinal barrier or blood-brain barrier and, therefore, must be administered centrally or intravitreally;
(2) it has a relatively short half-life; (3) at higher concentrations, it acts on the p75 NTR receptor, which has a pro-apoptotic effect. These limitations have led to the search for small molecule activators of TrkB. In a screen of small molecule libraries, Keqiang Ye and colleagues noted that compounds with an indole alkyl moiety, similar in structure to melatonin, N-acetylserotonin, and serotonin, had efficacy in promoting TrkB activation [13] .
Circadian Activation of TrkB in the Retina and Brain
Melatonin synthesis and AANAT activity occur as circadian rhythms with peaks at night in darkness [1;2] . The levels of pTrkB and total TrkB were examined during the day and night in two strains of mice [14] : C3H/f +/+ mice, which have an intact melatonin synthetic pathway [15] , and C57BL/6J mice, which have a mutation in AANAT that limits the production of melatonin [16] . Total TrkB protein did not evidently fluctuate as function of time of day in either strain of mouse. However, a circadian rhythm in the levels of pTrkB was observed in the retina and hippocampus of C3H/f +/+ mice, with higher levels at night compared to day. In contrast, pTrkB levels were similar in the day and night in the retina and hippocampus of C57BL/6J mice.
N-Acetylserotonin Activates TrkB and Its Signaling Pathways
To determine if endogenous indole alkyl compounds can activate TrkB, the effects of serotonin, N-acetylserotonin and melatonin on pTrkB were examined in cultured cortical and hippocampal neurons [14] . Treatment of cultures with BDNF and N-acetylserotonin, but not with serotonin, 5-hydroxyindoleacetic acid, or melatonin, increased the level of pTrkB assessed by immunofluorescence and immunoblot analyses [14] . The effect of Nacetylserotonin appeared to be specific for TrkB, as it had no effect on TrkA or TrkC. It was dose dependent and was observed in the low nM range. Systemic administration of Nacetylserotonin increased pTrkB in the retina and hippocampus, indicating that it crosses the blood-retinal and blood-brain barriers. This conclusion was verified by direct measurement of N-acetylserotonin in the retina and brain following systemic administration [17] . In vitro, N-acetylserotonin was shown to promote TrkB dimerization and activation of downstream signaling kinases, including ERK1/2 and AKT. The effects of N-acetylserotonin were BDNF-independent, as shown in neurons from forebrain-specific BDNF conditional knockout mice. They were blocked by 1NMPP1, a specific inhibitor of Trk tyrosine kinase in TrkB F616A knock-in mouse neurons [18] , indicating that they are specifically mediated by TrkB activation.
Neuroprotective Effect of N-Acetylserotonin
Kainic acid administration promotes neuronal apotoptosis in brains of TrkB F616A mice. The effect of kainic acid was antagonized by systemic administration of N-acetylserotonin, but not of melatonin [14] . Moreover, the neuroprotective effect of N-acetylserotonin was blocked by 1NMPP1, indicating that it was mediated by activation of TrkB. Similarly, BDNF and N-acetylserotonin effectively blocked glutamate-induced apoptosis in cultured cortical neurons [14] .
As mentioned, treatment with BDNF protects rats from LIRD [9] . In contrast, Nacetylserotonin had no protective effect against LIRD in mice, even at doses exceeding those required for maximal TrkB activation (K. Ghai and P.M. Iuvone, unpublished observations). The lack of neuroprotection could be due to species differences, protocol differences (constant light vs. short-term high-intensity light), or to the short half-life of Nacetylserotonin.
Neuroprotective Effect of HIOC, an N-Acetylserotonin Derivative
Several N-acetylserotonin derivatives were evaluated for efficacy in activating TrkB [17] . One of these, N- [2-(5- 
hydroxy-1H-indol-3-yl)ethyl]-2-oxopiperidine-3-carboxamide (HIOC)
was potent and effective in activating TrkB and downstream signaling kinases. HIOC passed the blood-brain and blood-retina barriers following systemic administration, as assessed by pharmacokinetic measurements of the drug in blood, retina and brain [17] . It had a significantly longer biological half-life than N-acetylserotonin, and promoted persistent activation of TrkB following systemic administration [17] . HIOC protected cultured neurons from glutamate-induced neuronal cell death. It also protected against kainic acid-induced apoptosis in the brain following systemic administration; the neuroprotective effect of HIOC was TrkB dependent. In contrast to N-acetylserotonin, HIOC potently protected against LIRD, as assessed functionally and histologically [17] . Bright-light exposure (8000 lux for 1 h) markedly reduced a-wave and b-wave amplitudes of the dark-adapted electroretinogram (ERG), measured one week post exposure, and caused reduced thickness of the outer nuclear layer (ONL) and photoreceptor outer segment disruption, measured 16 days post exposure ( Fig. 96.1) . These deleterious effects of bright light were significantly attenuated with HIOC treatment (Fig. 96.1) [17] . The neuroprotective effect of HIOC was tightly associated with TrkB activation. When assessed 90 min after bright light exposure in vehicle-treated mice, a small increase in pTrkB immunoreactivity was observed just distal to the ONL in the vicinity of photoreceptor inner segments [17] . This may reflect TrkB activation in the microvilli of Müller cells, as photoreceptors are not thought to express TrkB [19] . There was also some increase in label in cells of the ganglion cell layer. In the retinas of mice exposed to bright light and treated with HIOC, there was a massive increase of pTrkB labeling in the retina. The labeling at the level of the inner segments was greatly enhanced, as was that in ganglion cell and inner nuclear layers [17] . TrkB activation in the Müller cell microvilli may be particularly relevant to the photoreceptor-survival effect of HIOC considering its location and a previous study showing that BDNF expression directed to Müller cells is protective in LIRD [10] .
Conclusion
These recent studies suggest that N-acetylserotonin, previously thought to be just a precursor of melatonin, is an endogenous circadian neuroprotectant and activator of TrkB receptors. Exogenous N-acetylserotonin may have therapeutic benefit in short-term neurotoxic insults, but probably not for slowly developing neurodegenerative disease due to its short half-life. Synthetic, small molecule activators of TrkB based on the structure of N-acetylserotonin have potential for the treatment of retinal degenerative diseases and HIOC is a good lead compound for this purpose. 
